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We, herein, describe a 52-year-old male whom developed rhabdomyolysis and acute renal failure likely
related to dasatinib shortly after the administration of treatment. After withdrawal of dasatinib, the
myalgia reduced, and his CK returned to normal levels within a week. On follow-up acute renal failure
did resolve without requiring dialysis, but unfortunately the patient died of severe respiratory distress.
We recommend that musculoskeletal symptoms should be monitorized during therapy with dasatinib,
and CML patients with musculoskeletal symptoms should have CK levels checked in order to prevent this
unexpected but devastating adverse event.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).To the Editor,
Dasatinib, a second-generation BCR-ABL inhibitor that has 325-
fold higher potency in vitro compared with imatinib [1], is used for
the treatment of Philadelphia chromosome-positive (Phþ) chronic
myeloid leukemia (CML) and Phþ acute lymphoblastic leukemia.
Its common side effects (myelosuppression, ﬂuid retention, and
diarrhea) are most often mild and manageable [2]. All grades of
adverse reactions under dasatinib treatment including muscu-
loskeletal pain, myalgias, and muscle spasms are 13%, 6%, and 5%
respectively, based on the manufacturer's labeling. However, no
grade 3/4 adverse reactions of musculoskeletal system are de-
scribed, as well as rhabdomyolysis [3]. In the 2-year follow-up of
phase 3 DASISION (dasatinib versus imatinib study in treatment-
naive CML patients) study, one patient in the dasatinib arm dis-
continued treatment because of elevated skeletal creatine phos-
phokinase with no evidence of myocardial ischemia [1].
Among tyrosine kinase inhibitors (TKIs), imatinib mesylate-
induced two [4,5], and erlotinib-induced one [6] rhabdomyolysis
cases are documented. However, no dasatinib- or nilotinib-in-
duced rhabdomyolysis cases are reported in the current literatute.
To the best of our knowledge, this is the ﬁrst report of rhabdo-
myolysis which had been occurred under dasatinib treatment.
We describe here a case of a 52 year-old male who received
dasatinib (Sprycells, Bristol-Myers Squibb) at a daily dose of
100 mg for the treatment of chronic phase CML with no hemato-
logic or molecular response to imatinib-mesylate. Approximately
4 months ago he had been diagnosed as de novo chronic phase
CML, and imatinib mesylate (Glivecs, Novartis) 400 mg/day was
initiated. However, the patient's compliance to treatment was not
adequate. 4 months after imatinib therapy, he admitted to our in-
stitution. At that time neither hematologic nor molecular response
was achieved under imatinib therapy. Therefore, imatinib was
stopped and second-generation TKI (dasatinib) was given instead in
order to prevent disease progression. Two weeks after the admin-
istration of dasatinib treatment, he had severe lassitude and muscle
weakness, and an elevated level of serum creatine kinase (CK:Ltd. This is an open access article u2600 U/L, normal range: 25–195). His renal function tests on ad-
mission were as follows: urea: 143 mg/dL (10–50), creatinine:
3.0 mg/dL (0.6–1.2). His CK level peaked at 3831 U/L on the day
following admission. The patient's medical history was unremark-
able for chronic diseases and he was not taking any drugs that may
affect dasatinib metabolism or trigger rhabdomyoysis. There was no
history of trauma, direct injury, or excessive physical activity.
Myocardial infarction, stroke, medications (statins, antidepressants,
antipsychotic drugs, colchicine), or other common causes of rhab-
domyolysis were ruled out. He had not been using any alcohol or
other substances (e.g. herbal medicines). Dasatinib was stopped and
he was given aggressive hydration, allopurinol and diuretics. Be-
cause of the patient's low performance status, a muscle biopsy was
deferred at this point. After withdrawal of dasatinib, the myalgia
reduced, and the CK returned to normal levels (156 U/L) within a
week (Fig. 1). On follow-up acute renal failure did resolve without
requiring dialysis. Unfortunately, the patient died after clinical de-
terioration while receiving palliative therapy had progressive severe
respiratory distress, with a rapid decline in performance status ul-
timately leading to cardiorespiratory arrest. The leading cause of
death was thought to be severe pulmonary infection.
Although a clear association cannot be made between the ad-
ministration of dasatinib and the CK elevations based on this case
alone, we considered his rhabdomyolysis to be induced by dasa-
tinib. Our objectives are (a) the rhabdomyolysis occurred shortly
after the initiation of dasatinib therapy, (b) his CK levels normal-
ized after withdrawal of the aforementioned drug. The exact me-
chanism whereby dasatinib could cause rhabdomyolysis remains
unclear. It has been suggested that platelet-derived growth factor
receptor and c-abl which are expressed by muscle tissue are in-
hibited by imatinib mesylate treatment, and the reduction of these
enzymes could lead to CK elevation [7,8]. Because of the potency of
dasatinib over imatinib mesylate, the same mechanism should
also be suggested in this case.
An uncommon adverse event of dasatinib, rhabdomyolysis,
should be considered in the clinical setting of persistent musclender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Close monitorisation of creatine kinase (CK) levels of the patient during
follow-up.
B. Uz, I. Dolasik / Leukemia Research Reports 5 (2016) 1–22pain and elevated CK levels. We, therefore, recommend examining
musculoskeletal symptoms for CML patients during treatment
with dasatinib. CML patients with musculoskeletal symptoms
should have CK levels checked in order to prevent this devastating
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